However, outgoing President Joe Biden's recent decision to expand Medicare and Medicaid coverage could usher in a new lease ...

Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK1,025.00. The company’s shares closed yesterday ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $ 35 ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.